VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Valion Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.16−0.01 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $3.92M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$71.34 (−98.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.92
- Dividend yield
- –
- Free cash flow yield
- -374.26%
Fundamentals
- Net income
- -$18.75M
- EPS, diluted
- -$7.77
- Free cash flow
- -$14.67M
- Book value per share
- $1.26
- Diluted shares
- 3M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$16.52M
Net income
-$18.75M
EPS, diluted
-$7.77
Free cash flow
-$14.67M
Reported periodTrailing twelve months